Entrada Therapeutics, Inc.
TRDA
$11.88
-$0.71-5.64%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -319.04% | -288.27% | -170.23% | 5.52% | 1,081.69% |
| Total Depreciation and Amortization | 8.56% | 19.48% | 14.50% | 17.04% | 32.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 101.82% | 90.91% | 56.87% | 52.84% | 7.71% |
| Change in Net Operating Assets | 95.96% | 46.15% | 48.96% | 23.93% | -187.19% |
| Cash from Operations | -209.24% | -815.96% | -772.86% | 38.79% | -129.73% |
| Capital Expenditure | 67.04% | 46.18% | 37.49% | 27.59% | 43.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 578.28% | 343.83% | -45.22% | 31.81% | 81.44% |
| Cash from Investing | 520.20% | 327.07% | -47.17% | 31.53% | 79.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.14% | -97.95% | -97.96% | 5,940.95% | 389.49% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.14% | -97.95% | -97.98% | 5,940.30% | 389.44% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -132.18% | -41.77% | -206.88% | 99.62% | 49.74% |